<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01801618</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS12276 2PICAM</org_study_id>
    <nct_id>NCT01801618</nct_id>
  </id_info>
  <brief_title>National Evaluation of PI-based 2nd Line Efficacy in Cambodia</brief_title>
  <official_title>National Evaluation of PI-based 2nd Line Efficacy in Cambodia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Medium and long term efficacy of PI-based 2nd line antiretroviral (ARV) therapy in Cambodia
      is poorly documented when the numbers of patients on treatment and their duration are
      increasing. For patients in treatment failure , there is no alternative ARV regimen available
      to date.

      This operational research aims to evaluate the Cambodian National Program PI-based 2nd line
      antiretroviral regimen to assess the proportion of treatment failure and drug resistance
      ;identify the structural and individual factors associated with treatment failure ; design
      alternative salvage ARV regimens.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Prevalence of virological failure</measure>
    <time_frame>at month 4</time_frame>
    <description>Virological failure is defined as an HIV viral load above 250 copies/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of drug resistance</measure>
    <time_frame>at inclusion</time_frame>
    <description>Sequencing of reverse transcriptase (RT), protease (PR) and integrase (IN) HIV genes.
HIV drug resistance is defined by the presence of resistance associated mutations inducing resistance according to the ANRS algorithm to one or more drugs in the standard second line regimen(s) used in Cambodia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of individual risk factors associated with treatment failure</measure>
    <time_frame>at inclusion</time_frame>
    <description>Individual factors will be collected at enrolment by a standardized questionnaire administered during a face to face 20 minutes interview by a trained member of the healthcare team. The questionnaire investigate adherence, perception of side effect, socio-economic status, disclosure and discrimination issues.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of structural risk factors associated with treatment failure</measure>
    <time_frame>At study initiation</time_frame>
    <description>Structural risk factors will be collected at the beginning of the study in each participating site through a standardized questionnaire including information on episodes of ARV stock-outs, task-shifting of HIV-care from physician to nurses, availability of psychosocial support, health service provider/patient ratio and health care provider availabilities, quality control, site activities indicators. The questionaire will be filled by the site project coordinator together with the coordinating project social science team.</description>
  </secondary_outcome>
  <enrollment type="Actual">15001351</enrollment>
  <condition>HIV</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma HIV RNA and cDNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All HIV-1 infected adults receiving a PI-based 2nd line regimen in one of the 13
        participating national program ARV treatment sites.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infection

          -  age above 18 years

          -  current PI based 2nd line ARV treatment since at least 6 months

          -  willing to participate and consent signature

        Exclusion Criteria:

          -  ongoing PI based 2nd line regimen for less that 6 months at time of study intake
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vonthanak Saphonn, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cambodian National Center of HIV/AIDS, Dermatology and STDs (NCHADS)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Nerrienet, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Pasteur, Paris France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno Spire, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Observatoire Régional de la Santé, Marseille, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Battambang Hospital</name>
      <address>
        <city>Battambang</city>
        <country>Cambodia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chey Chum Neah Hospital</name>
      <address>
        <city>Chey Chum Neah</city>
        <country>Cambodia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daun Keo Hospital</name>
      <address>
        <city>Daun Keo</city>
        <country>Cambodia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kampong Cham Hospital</name>
      <address>
        <city>Kampong Cham</city>
        <country>Cambodia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neak Loeung Hospital</name>
      <address>
        <city>Neak Loeung</city>
        <country>Cambodia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calmette Hospital</name>
      <address>
        <city>Phnom Penh</city>
        <country>Cambodia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Center</name>
      <address>
        <city>Phnom Penh</city>
        <country>Cambodia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khmero-Soviet Friendship Hospital</name>
      <address>
        <city>Phnom Penh</city>
        <country>Cambodia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preah Kossamak Hospital</name>
      <address>
        <city>Phnom Penh</city>
        <country>Cambodia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preahketomealea Hospital</name>
      <address>
        <city>Phnom Penh</city>
        <country>Cambodia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Social Health Clinic</name>
      <address>
        <city>Phnom Penh</city>
        <country>Cambodia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siem Reap Hospital</name>
      <address>
        <city>Siem Reap</city>
        <country>Cambodia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sihanouk Ville Hospital</name>
      <address>
        <city>Sihanouk Ville</city>
        <country>Cambodia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cambodia</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2013</study_first_submitted>
  <study_first_submitted_qc>February 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2013</study_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>PI based 2nd line ARV treatment</keyword>
  <keyword>Virological failure</keyword>
  <keyword>Drug resistance</keyword>
  <keyword>Cambodia</keyword>
  <keyword>Adherence</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

